Articles published by Samsung Bioepis Co., Ltd.

Samsung Bioepis Releases First Quarter 2026 US Biosimilar Market Report, Providing Updates to Evolving Drug Pricing Models

January 23, 2026

From Samsung Bioepis Co., Ltd.

Via Business Wire

Samsung Bioepis Releases Fourth Quarter 2025 US Biosimilar Market Report Providing Annual Biosimilar Trends and Future Market Trajectory

October 23, 2025

From Samsung Bioepis Co., Ltd.

Via Business Wire

Samsung Bioepis Releases Third Quarter 2025 US Biosimilar Market Report Exploring the Most-Favored-Nation (MFN) Policy and its Impact on Biosimilars

July 21, 2025

From Samsung Bioepis Co., Ltd.

Via Business Wire

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

July 17, 2025

From Samsung Bioepis Co., Ltd.

Via Business Wire

Samsung Bioepis’ Second Quarter 2025 Biosimilar Market Report Highlights US Debut of Ustekinumab Biosimilars with WAC discounts over 80% and Regulatory Streamlining

April 24, 2025

From Samsung Bioepis Co., Ltd.

Via Business Wire

Samsung Bioepis Announces US Launch of PYZCHIVA® (ustekinumab-ttwe), Biosimilar to Stelara

February 24, 2025

From Samsung Bioepis Co., Ltd.

Via Business Wire

FDA Approves Samsung Bioepis’ OSPOMYV™, XBRYK™ (denosumab-dssb), a Biosimilar to Prolia and Xgeva

February 15, 2025

From Samsung Bioepis Co., Ltd.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Samsung Bioepis Co., Ltd.

Starting at $3.75/week.

Subscribe Today